'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study - Reuters

Endpoints News

'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study Reuters (Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, early stage study ... CAR T-Cell Therapies Drive Outcomes in Lymphoma, MyelomaPR Newswire (press release) #ASH17: The BCMA-targeted CAR-T bb2121 from bluebird and Celgene takes a star turn in the spotlightEndpoints News all 7 news articles »

from Health - Google News http://ift.tt/2jFI6mR